Physician profile
Christin E Honaker
NPI 1023199064
$3,414.82
in general payments reported to CMS, 2019-2025
23 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $816 · 2021: $559 · 2022: $560 · 2023: $535 · 2024: $362 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $584.37 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $538.71 | 2019-2023 | Farxiga, Breztri |
| Abbvie INC. | $341.55 | 2021-2025 | |
| Allergan, INC. | $296.07 | 2019-2020 | |
| Lilly USA, LLC | $242.09 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $241.29 | 2019-2025 | |
| Amarin Pharma, INC. | $192.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $173.61 | 2021-2023 | |
| Glaxosmithkline, LLC. | $136.90 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $105.44 | 2020-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $87.58 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $81.82 | 2020-2021 | |
| Astellas Pharma US INC | $73.23 | 2020-2024 | Veozah |
| Boston Scientific Corporation | $64.37 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.91 | 2019-2023 | Jardiance, Tradjenta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.58 | 2022-2024 | Freestyle Libre 3, Freestyle Libre |
| Janssen Pharmaceuticals, INC | $44.94 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $26.88 | 2021 | |
| Axsome Therapeutics, INC. | $19.03 | 2025 | Auvelity |
| Shire North American Group INC | $17.09 | 2019 | |
| Nevro Corp. | $14.97 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.65 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christin Honaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.